Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Tipranavir (Aptivus®) oral solution. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2110. 2010 Authors' conclusions Tipranavir (Aptivus®) oral solution, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.
Tipranavir (Aptivus®) oral solution is not suitable for shared care within NHS Wales for the above indication. Indexing Status Subject indexing assigned by CRD MeSH Anti-HIV Agents; HIV Infections; Pyridines; Pyroness Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000370 Date abstract record published 08/08/2012 |